Am J Clin Exp Urol 2025;13(5):348-359
www.ajceu.us /ISSN:2330-1910/AJCEU0169279

Review Article

Artificial intelligence in prostate cancer: navigating the new frontier of precision uro-oncology

Ming Liu[1], Lingfeng Li[1], Soroush Rais-Bahrami[2,3,4], Ashok K Hemal[2,3], Anthony Atala[2,5], Yuanyuan Zhang[3,5]

[1]Department of Urology, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China; [2]Department of Urology, Wake Forest University School of Medicine, Winston-Salem, NC, USA; [3]Wake Forest Baptist Comprehensive Cancer Center, Wake Forest University School of Medicine, Winston-Salem, NC, USA; [4]Center for Artificial Intelligence Research, Wake Forest University School of Medicine, Winston-Salem, NC, USA; [5]Wake Forest Institute for Regenerative Medicine, Wake Forest University School of Medicine, Winston-Salem, NC, USA

Received October 12, 2025; Accepted October 23, 2025; Epub October 25, 2025; Published October 30, 2025

Abstract: Artificial Intelligence (AI) is revolutionizing prostate cancer (PCa) care, addressing the major clinical challenges of subjectivity and overtreatment. Our traditional tools - like PSA, DRE, mpMRI, and Gleason scoring - often lack the precision needed to distinguish truly aggressive tumors from indolent disease, leading to unnecessary morbidity in up to 50% of low-risk men. This review explains how AI, specifically machine learning (ML) and deep learning (DL), is poised to solve this. We cover AI's role from initial diagnosis, where radiomics and digital pathology boost grading accuracy and reduce inter-reader variability, to treatment selection and surgical precision through predictive models and Augmented Reality (AR) guidance. We also detail its utility in predicting biochemical recurrence (BCR) and managing long-term side effects. Finally, we address the critical barriers to adoption, including the need for large, diverse datasets (to combat algorithmic bias), the "black box" problem (solved by Explainable AI, XAI), and navigating FDA regulation. The future of PCa care hinges on this precise, data-driven approach.

Keywords: Prostate cancer, artificial intelligence, machine learning, deep learning, radiomics, uro-oncology, clinical decision support, personalized medicine

Introduction

Prostate cancer (PCa) remains a global health crisis, demanding better tools to manage its wide spectrum, from harmless to lethal. Our current diagnostic methods - including mpMRI interpretation, PSA testing, digital rectal examination (DRE), and Gleason grading - remain limited by interobserver variability and poor specificity. Inter-reader disagreement for mpMRI and the low positive predictive value of serum PSA contribute to unnecessary biopsies and overtreatment, resulting in substantial morbidity. Recent analyses emphasize the urgent need for standardized interpretation systems and AI-assisted imaging tools to improve reproducibility and diagnostic precision [1-4]. Notably, integration of AI with multimodal biomarkers such as urinary or serum multi-marker assays shows potential to enhance noninvasive screening accuracy and reduce biopsy burden [5, 6]. This imprecision is costly: it contributes to overtreatment, resulting in unnecessary incontinence and erectile dysfunction for approximately 50% of low-risk patients [7]. The need for precise risk stratification is amplified by health disparities: Black men face a PCa incidence rate 70% higher and a mortality rate two to three times higher than White men, highlighting the urgency for objective, equitable diagnostic tools. Our clinical goal is straightforward: accurately identify the lethal tumors while safely watching the indolent ones.

Artificial Intelligence (AI) offers a powerful new framework. Over the past decade, AI-based systems have rapidly evolved from simple pattern-recognition tools to comprehensive analytical platforms capable of integrating heterogeneous biomedical data. AI consists of Machine

https://doi.org/10.62347/ZTWJ5779

Learning (ML) (like Random Forests) and Deep Learning (DL), which uses complex Convolutional Neural Networks (CNNs) especially good at image analysis. In urologic oncology, CNN-based models have demonstrated excellent performance in lesion detection and Gleason grading on multiparametric MRI, as well as in segmentation tasks that previously required expert radiologists [8]. ML algorithms such as random forests, support vector machines, and gradient boosting have been successfully applied to clinical and biochemical datasets (e.g., PSA kinetics, age, comorbidities) to improve diagnostic and prognostic accuracy [9].

AI sifts through massive, complex datasets (imaging, genomics, EHR data) to find patterns invisible to the human eye [10]. By integrating radiomic, genomic, and clinical variables into a single analytical pipeline, AI facilitates a more holistic understanding of tumor biology - bridging the gap between imaging phenotypes and molecular alterations. For example, radiogenomic models have linked mpMRI features with genomic signatures such as PTEN loss and TMPRSS2-ERG fusion, offering the possibility of non-invasive molecular profiling. Additionally, natural language processing (NLP) methods can extract key prognostic information from unstructured EHR or pathology reports, enhancing data completeness and reducing human workload [11]. This computational power is our path to precision uro-oncology, moving beyond generalized guidelines toward highly personalized patient management. Instead of treating prostate or bladder cancer as homogeneous entities, AI allows stratification of patients into molecular and clinical subtypes with distinct therapeutic needs and prognoses. Ultimately, AI-driven insights will enable individualized treatment decisions - optimizing biopsy strategies, predicting therapeutic response, and improving survival outcomes through truly precision-based care.

AI in diagnosis and risk stratification

Radiomics and imaging

AI is transforming how we read Radiomics and Imaging (mpMRI): Radiomics uses DL to extract hundreds of quantitative features (texture, shape) from mpMRI to create a detailed “signature” of the tumor [2, 12, 13]. CNN models are trained to: a). Automate Segmentation: Quickly contour the prostate and key anatomy (a process that currently takes radiologists several minutes). Automated segmentation not only saves time but also minimizes inter-observer variability, providing consistent and reproducible regions of interest for downstream analysis [14]. B). PI-RADS & Gleason Prediction: Automatically identify suspicious lesions using PI-RADS criteria and, more critically, directly predict the Gleason score and tumor volume from the images [15]. Studies show AI models achieve diagnostic accuracy (AUC) for clinically significant PCa comparable to, and often slightly exceeding (AUC up to 0.90), expert radiologists [16, 17]. This capability significantly improves the yield of targeted biopsies and reduces the necessity of systematic, random sampling. Furthermore, AI can use preoperative imaging to predict extraprostatic extension (EPE) [18-23], providing crucial T-stage information for surgical planning. Standardized public datasets and consensus contour atlases are now available to improve reproducibility across institutions [4, 24]. Multi-institutional radiomic pipelines, such as the ProstateX and PROMISE12 challenges, have established benchmark datasets and evaluation metrics that enable fair comparison across algorithms and encourage transparency and generalizability [25]. Together, these advances mark a decisive step toward robust, clinically deployable AI-driven mpMRI interpretation.

Pathology and histology

Pathology is ideal for AI. The major issue is inter-pathologist variability, especially in distinguishing intermediate-risk disease (Gleason Grade Groups 2 and 3). DL models, as validated in large-scale efforts like the PANDA Challenge [26, 27], can perform automated and reproducible Gleason grading with extremely high concordance (AUC>0.95 across multiple institutions) [3, 28, 29]. Additional studies have shown that AI-based pathology systems can improve diagnostic efficiency and reduce interobserver variability across institutions [3, 30]. Recent bibliometric analyses also reveal exponential growth in AI pathology research, highlighting the emergence of federated learning and explainable models for histopathologic interpretation [31-33]. Federated learning allows AI models to be trained collaboratively across multiple centers without the need to share raw patient data, addressing both privacy and diversity challenges. At the same time, explainable AI (XAI) methods are increasingly incorporated to visualize which histologic regions drive the model's predictions, enhancing interpretability and trust among clinicians [34]. Such developments provide the foundation for clinically deployable digital pathology systems. This objective grading is vital, as it directly governs whether a patient is placed on active surveillance or proceeds to curative therapy.

AI also excels at rapidly quantifying tumor volume and assisting with the challenging task of surgical margin assessment on prostatectomy specimens. Automated margin detection algorithms can highlight suspicious residual foci in real time, reducing the risk of false negatives and aiding intraoperative decision-making [35]. New histology-enabled workflows (e.g., stimulated Raman histology) and integrated pathology image-management systems are shortening the path from WSI acquisition to AI-assisted diagnosis, improving throughput and consistency in routine reporting [36-38]. Stimulated Raman histology (SRH) provides label-free, high-resolution tissue imaging that can be analyzed directly by AI models, offering near-instantaneous histopathologic feedback during surgery. Together, these innovations move digital pathology from a research tool toward a fully integrated, clinically actionable component of prostate cancer care.

Multi-modal data integration

ML's greatest strength is fusing complex data. ML algorithms can combine clinical data (PSA kinetics, age), imaging features (radiomics), and genomic data (e.g., mRNA panels) to produce a highly precise, personalized risk score [39-43]. Recent multimodal frameworks have demonstrated that integrating mpMRI-derived quantitative features with serum biomarkers and genomic signatures significantly enhances the discrimination of clinically significant prostate cancer (csPCa) compared with unimodal models. For example, combining PI-RADS scores, PSA density, and transcriptomic classifiers improves both diagnostic and prognostic accuracy, enabling more refined patient stratification. This multi-modal approach is the key to identifying patients who are genuinely low-risk and suitable for active surveillance, safely managing up to 50% of newly diagnosed PCa cases without intervention-related side effects [44, 45]. Furthermore, XAI and federated learning pipelines are increasingly being explored to allow multi-institutional model training while preserving data privacy, ensuring that these integrative tools can be ethically and securely deployed in real-world clinical workflows.

AI in treatment selection and surgical planning

Predictive modeling for treatment choice

AI models are superior to conventional nomograms in forecasting adverse outcomes. By leveraging large, well-annotated clinical and pathologic datasets, AI/ML models capture complex, nonlinear interactions among risk factors that traditional nomograms may miss. Trained on large outcome databases, these ML models can predict a patient's individualized risk of positive surgical margins or biochemical recurrence (BCR) after radical treatment [46-48]. By integrating patient-reported Quality of Life (QoL) data, AI facilitates shared decision-making, allowing a patient to weigh a projected survival benefit against their personalized risk of post-prostatectomy incontinence. In conceptual and pilot frameworks, models that include baseline urinary/sexual function scores or patient preference parameters can present trade-off curves (e.g. survival vs incontinence risk) to patients and clinicians, thereby supporting truly personalized therapeutic choice.

Radiotherapy: AI automates the time-intensive process of Organ-at-Risk (OAR) segmentation (e.g., bladder, rectum) [24, 49, 50], cutting planning time from hours to minutes and improving the consistency and quality of radiation delivery. By standardizing contours and reducing inter- and intra-observer variability, AI ensures that dose constraints to critical structures are more reliably respected, thus minimizing toxicity. These advances have been applied to MR-guided adaptive radiotherapy and proton-dose estimation workflows to support faster, patient-specific planning. In MR-Linac systems, AI-driven auto-contouring enables near real-time adaptation of treatment plans to daily anatomy changes, reducing latency from imaging to plan delivery. For proton therapy,



Figure 1. The Deep Learning Pipeline in Digital Pathology (Technical Focus) in diagnosis prostate cancer. This diagram illustrates the typical deep learning pipeline used for the automated analysis and diagnosis of PCa from digitized tissue samples. *Whole Slide Image (WSI) Acquisition:* The process begins with a Whole Slide Image (WSI), which is a high-resolution digital representation of a stained histology glass slide, typically using Hematoxylin and Eosin (H&E). The WSI serves as the input for the computational model. *Deep Learning Processing:* The WSI is fed into a Deep Learning model (e.g., a Convolutional Neural Network or CNN), represented schematically by a network of interconnected nodes. This model is trained to recognize subtle, complex morphological patterns indicative of cancer (PCa). *AI-Generated Heatmap:* The output is an AI-Generated Heatmap, which visually overlays the tissue image with color-coded confidence scores. Red/yellow areas indicate regions of high model certainty (i.e., high probability of containing PCa/malignancy), while blue/purple areas represent low certainty/benign regions. *XAI Insights:* The heatmap acts as the visual foundation for Explainable Artificial Intelligence (XAI) Insights, providing transparency into the model's decision-making process. The heatmap explicitly shows *which specific tissue regions* drove the model's final PREDICTION (e.g., a diagnosis of positive for PCa or a specific Gleason score). This allows pathologists to validate the AI's results and enhances trust in the digital pathology workflow *(Created by Co-pilot program*). Abbreviations: WSI: Whole Slide Image, PCa: Prostate Cancer. H&E: Hematoxylin and Eosin (Stain); CNN: Convolutional Neural Network (Implied Deep Learning Architecture), XAI: Explainable Artificial Intelligence.

AI-facilitated online adaptive workflows (oAPT) integrate auto-segmentation with robust re-optimization and dose recalculation to adjust to anatomical shifts, achieving clinically acceptable re-plans in ~9 minutes for prostate cases [51]. Such integration accelerates planning turnaround, supports personalized dose painting, and paves the way for fully adaptive, precision radiotherapy pipelines.

Robotic surgery and surgical planning

AI is enhancing robotic-assisted surgery, the approach used in over 80% of radical prostatectomies in the US [52].

Preoperative planning: AI analyzes preoperative mpMRI to create a high-fidelity 3D map of the tumor and critical structures like neurovascular bundles [53, 54]. This map can be integrated into the surgical console to provide real-time Augmented Reality (AR) guidance, aiming to improve the precision of the nerve-sparing procedure and minimize post-operative QoL morbidity [55-57]. Image-fusion pipelines (MRI→TRUS) and standardized contour atlases are being used to benchmark and deploy these models in surgical practice.

Intraoperative assistance: Deep learning algorithms are now capable of real-time semantic segmentation of surgical video, automatically identifying key anatomical landmarks and assisting with instrument tracking [58] (**Figure 1**). Future AI systems are expected to act as "intelligent co-pilots", continuously analyzing surgical video streams to provide automated performance metrics, detect potential errors, and deliver real-time feedback on technique [59, 60]. Such advancements have the potential to standardize surgical performance, enhance training, and further improve postoperative functional and oncologic outcomes.

Focal therapy and targeted ablation

For focal therapy (like HIFU or cryoablation), precise tumor targeting is everything. AI-driven tools accurately contour tumor boundaries and treatment margins on mpMRI (often within 1 mm accuracy) [61-63], ensuring complete tumor ablation while critically preserving surrounding healthy tissue and function. Preclinical and early clinical studies of AI-assisted ablation planning and image-guided RFA/HIFU demonstrate feasible integration with existing focal-therapy workflows [64, 65].

AI in prognosis and post-treatment care

Prediction of recurrence

Accurate prediction of BCR is vital for timely salvage therapy. AI models forecast the risk of BCR with greater accuracy and earlier warning than traditional clinical cut-offs [66, 67]. These models - ranging from time-dependent survival learners (e.g., Random Survival Forests) to deep learning systems trained on histology and multimodal inputs - provide both higher discrimination and improved temporal resolution for when recurrence is likely to occur (**Figure 1**). They analyze post-treatment PSA kinetics (e.g., PSA doubling time, velocity) along with initial pathological and treatment factors, such as margin status, Gleason grade group, lymph node involvement, and adjuvant therapies, to refine individualized risk estimates and to distinguish indolent PSA rises from clinically meaningful recurrence [68, 69]. By incorporating serial PSA measurements as time-series features (or explicitly modeling time-to-event with time-dependent covariates), ML methods can deliver earlier warnings than static cut-offs (for example, flagging subtle upward trends in PSA-DT that precede threshold crossings), thus enabling more proactive surveillance. This capability allows clinicians to triage patients for earlier salvage interventions - such as salvage radiation or ADT - when predicted risk trajectories justify treatment, while sparing low-risk individuals from unnecessary interventions and their side effects [70].

Managing treatment-related side effects

AI provides high-impact support for QoL management. By learning from large surgical and radiotherapy outcome datasets, these models can uncover complex interactions among patient anatomy, comorbidities, baseline function, and treatment parameters that standard risk scores cannot capture. It predicts which patients are at highest risk for complications like erectile dysfunction or urinary incontinence based on pre-treatment factors and surgical/dosimetric details [71-73]. This predictive capability allows clinicians to implement targeted pre-habilitation and tailored post-operative management strategies. For instance, high-risk patients identified by AI can be prioritized for intensive pre-operative pelvic floor physical therapy.

Overcoming challenges

Data and validation: the generalizability hurdle

The performance of any AI model depends entirely on its training data. The challenge of algorithmic bias is particularly pressing in PCa: data from high-risk minority groups, like Black men, are often underrepresented in training cohorts [74, 75]. This reliance on non-diverse data leads to models that may perform poorly when applied to these high-risk populations.

Multi-institutional, federated learning (allowing models to train across centers without sharing patient data) and dedicated efforts to ensure highly diverse training cohorts are essential for generalizability and equitable care (**Table 1**) [76].

Interpretability and trust: the "black box" problem

Clinicians are understandably hesitant to base life-altering treatment decisions on a complex DL model whose rationale is opaque - the "black box" problem.

Explainable AI (XAI) provides transparency by offering clear justifications for AI recommendations, for example, by highlighting the specific microscopic features that led to a high-grade pathology prediction (**Table 1**) [77, 78]. XAI is necessary to build clinical trust and facilitate regulatory oversight [79, 80].

Ethical and regulatory considerations

The FDA and similar bodies are actively creating clear approval pathways for AI as a Soft-

Table 1. Challenges and solutions for clinical translation

Challenge	Description	Proposed Solution/Future Direction
Generalizability/Bias	Models trained on single-institution/homogeneous data fail in new clinics.	Multi-institutional data collaboration; Federated Learning; Diverse patient cohorts (ethnicity, geography).
The "Black Box" Problem	Lack of transparency in complex DL model decision-making.	Explainable AI (XAI) techniques (e.g., heatmaps, attention maps); Clinician-in-the-loop validation.
Regulatory & Ethical Hurdles	Need for clear approval pathways and accountability for AI-driven errors.	FDA/EMA framework for Software as a Medical Device (SaMD); Mandatory post-market surveillance.
Workflow Integration	AI tools operate outside existing EHR/PACS systems, creating workflow friction.	Seamless integration of AI-driven CDS tools directly into the clinical interface; API standardization.

Table 2. AI across the prostate cancer continuum

Stage of PCa Care	AI Application	Input Data	Output/Clinical Impact
Screening/Risk	Personalized Risk Prediction	PSA, Clinical Factors, Genomics	Refined stratification; Select active surveillance candidates.
Diagnosis	Deep Learning for Imaging/Pathology	mpMRI (T2W, ADC, DCE), Whole Slide Images (WSI), Patho-histological Analysis	Automated PI-RADS scoring; Objective Gleason grading (GG 1-5).
Treatment Planning	Predictive Modeling/AR Guidance	Radiomics, Pathological features, Surgical Video	Prediction of positive margins; Real-time Nerve-Sparing guidance.
Follow-up/Prognosis	ML for Recurrence	Post-treatment PSA kinetics, Clinical data	Timely prediction of BCR; QoL prediction (incontinence/ED risk).

ware as a Medical Device (SaMD) [81]. Central to this is the requirement for rigorous real-world validation and post-market surveillance of "locked" algorithms. Furthermore, AI tools must be seamlessly integrated into existing EHR and PACS systems to prevent workflow disruption [82].

The potential for AI is vast. Large Language Models (LLMs) could revolutionize workflow by analyzing unstructured clinical notes, summarizing complex patient histories, and assisting with documentation [83, 84]. The ultimate goal is a fully integrated, AI-driven Clinical Decision Support (CDS) system that synthesizes all available data - imaging, pathology, genomics - to provide real-time, actionable insights at the point of care (**Table 2**) [85-87].

Future directions and clinical integration

The next frontier of AI in PCa will focus on moving from single-task validation to integrated, multi-modal clinical decision support systems (CDSS):

Holistic risk stratification: Future AI models must integrate multimodal data - combining Whole Slide Images (WSI), multiparametric MRI (mpMRI), liquid biopsy markers, genomic/transcriptomic data, and clinical history (e.g., PSA kinetics) - to produce comprehensive risk scores. This allows for a more accurate distinction between indolent and clinically significant PCa than current single-modality approaches.

Active Surveillance (AS) optimization: AI will be crucial for refining the selection criteria for AS and minimizing the risk of under-treatment. Models will use longitudinal data to predict which AS patients are most likely to progress, guiding timely intervention and reducing unnecessary repeat biopsies.

Therapeutic personalization: AI-driven predictive analytics will forecast individual patient response to various treatments (e.g., radical prostatectomy, radiation therapy, and novel hormonal agents). This enables clinicians to select the optimal treatment and sequencing, thereby maximizing efficacy while minimizing treatment-related toxicity and side effects.

Robotic surgery enhancement: AI-powered computer vision and intraoperative sensing will advance the autonomy and precision of robotic platforms, aiding in real-time tumor margin detection and the preservation of crucial structures (e.g., neurovascular bundles) to improve functional outcomes like continence and potency.

Challenges to clinical translation and widespread adoption

Moving beyond proof-of-concept studies requires addressing several critical, non-technical barriers:

Rigorous validation and generalizability: The current reliance on retrospective, single-institution datasets must transition to rigorous, multi-institutional, prospective clinical trials with diverse patient cohorts. This is essential to ensure AI models maintain their high-performance metrics when deployed across different scanners, pathology labs, and patient demographics.

Data governance and standardization: Success hinges on establishing standardized data acquisition protocols (e.g., WSI and mpMRI formats) and secure, federated data-sharing networks. Regulatory bodies (like the FDA and EMA) must also finalize clear, adaptive frameworks for Software as a Medical Device (SaMD) to facilitate safe and timely deployment.

The Mandate for Explainable AI (XAI): Clinician trust is paramount. Transparent XAI principles are not optional; they are required to demystify the "black-box" nature of deep learning. XAI tools, such as heatmaps and saliency maps, must provide actionable, visual insights that pathologists and radiologists can readily interpret and validate, ensuring that the AI functions as a collaborative augmentative tool rather than an autonomous replacement (**Figure 1**).

Conclusion

Artificial Intelligence, particularly through DL models, represents a transformative force in the landscape of PCa management. It has demonstrated promising potential to move beyond the current limitations of diagnostic subjectivity and generalized treatment protocols, primarily by improving diagnostic accuracy (e.g., automated Gleason grading and PI-RADS scoring) and facilitating precise, personalized treatment strategies. The ultimate successful integration of this technology is intrinsically linked to the future of precision uro-oncology. The successful, ethical, and equitable integration of AI into uro-oncology demands sustained interdisciplinary collaboration among urologists, pathologists, radiologists, radiation oncologists, and data scientists. By prioritizing robust external validation, transparent XAI, and comprehensive regulatory oversight, the medical community can fully harness AI's power to deliver a new standard of precise, efficient, and patient-centric PCa care.

Acknowledgements

The authors wish to thank the Department of Defense (DoD) Prostate Cancer Research Program (PCRP) for their generous support of this work through an Idea Development Award (Grant Number: HT94252510856) (YZ, PI).

Disclosure of conflict of interest

None.

Address correspondence to: Yuanyuan Zhang, Wake Forest Institute for Regenerative Medicine, Wake Forest University School of Medicine, Winston-Salem, NC, USA. E-mail: Yuanyuan.Zhang@Advocatehealth.org

References

[1] Goldenberg SL, Nir G and Salcudean SE. A new era: artificial intelligence and machine learning in prostate cancer. Nat Rev Urol 2019; 16: 391-403.

[2] Song Y, Zhang YD, Yan X, Liu H, Zhou M, Hu B and Yang G. Computer-aided diagnosis of prostate cancer using a deep convolutional neural network from multiparametric MRI. J Magn Reson Imaging 2018; 48: 1570-1577.

[3] Ström P, Kartasalo K, Olsson H, Solorzano L, Delahunt B, Berney DM, Bostwick DG, Evans AJ, Grignon DJ, Humphrey PA, Iczkowski KA, Kench JG, Kristiansen G, van der Kwast TH, Leite KRM, McKenney JK, Oxley J, Pan CC, Samaratunga H, Srigley JR, Takahashi H, Tsuzuki T, Varma M, Zhou M, Lindberg J, Lindskog C, Ruusuvuori P, Wählby C, Grönberg H, Rantalainen M, Egevad L and Eklund M. Artificial intelligence for diagnosis and grading of prostate cancer in biopsies: a population-based, diagnostic study. Lancet Oncol 2020; 21: 222-232.

[4] Turkbey B, Huisman H, Fedorov A, Macura KJ, Margolis DJ, Panebianco V, Oto A, Schoots IG, Siddiqui MM, Moore CM, Rouvière O, Bittencourt LK, Padhani AR, Tempany CM and Haider MA. Requirements for AI development and reporting for MRI prostate cancer detection in biopsy-naive men: PI-RADS steering committee, version 1.0. Radiology 2025; 315: e240140.

[5] Kim H, Park S, Jeong IG, Song SH, Jeong Y, Kim CS and Lee KH. Noninvasive precision screening of prostate cancer by urinary multimarker sensor and artificial intelligence analysis. ACS Nano 2021; 15: 4054-4065.

[6] Crocetto F, Musone M, Chianese S, Conforti P, Digitale Selvaggio G, Caputo VF, Falabella R, Del Giudice F, Giulioni C, Cafarelli A, Lucarelli G, Busetto GM, Ferro M, Barone B, Zattoni F and Terracciano D. Blood and urine-based biomarkers in prostate cancer: current advances, clinical applications, and future directions. J Liq Biopsy 2025; 9: 100305.

[7] Dushimova Z, Iztleuov Y, Chingayeva G, Shepetov A, Mustapayeva N, Shatkovskaya O, Pashimov M and Saliev T. Overdiagnosis and overtreatment in prostate cancer. Diseases 2025; 13: 167.

[8] Yilmaz EC, Belue MJ, Turkbey B, Reinhold C and Choyke PL. A brief review of artificial intelligence in genitourinary oncological imaging. Can Assoc Radiol J 2023; 74: 534-547.

[9] Xiao LH, Chen PR, Gou ZP, Li YZ, Li M, Xiang LC and Feng P. Prostate cancer prediction using the random forest algorithm that takes into account transrectal ultrasound findings, age, and serum levels of prostate-specific antigen. Asian J Androl 2017; 19: 586-590.

[10] Miotto R, Wang F, Wang S, Jiang X and Dudley JT. Deep learning for healthcare: review, opportunities and challenges. Brief Bioinform 2018; 19: 1236-1246.

[11] Huang H, Lim FXY, Gu GT, Han MJ, Fang AHS, Chia EHS, Bei EYT, Tham SZ, Ho HSS, Yuen JSP, Sun A and Lim JKS. Natural language processing in urology: automated extraction of clinical information from histopathology reports of uro-oncology procedures. Heliyon 2023; 9: e14793.

[12] Zhang C, Wang Z, Shang P, Zhou Y, Zhu J, Xu L, Chen Z, Yu M and Zang Y. Combining multiparametric MRI radiomics features with tumor abnormal protein to construct a machine learning-based predictive model for prostate cancer. Sci Rep 2025; 15: 22816.

[13] Zhang Z, Yang Q, Shiradkar R, Mirtti T, Azamat S, Xuan K, Xu J and Madabhushi A. A deep learning derived prostate zonal volume-based biomarker from T2-weighted MRI to distinguish between prostate cancer and benign prostatic hyperplasia. Med Phys 2025; 52: e18053.

[14] Pellicer-Valero OJ, Marenco Jiménez JL, Gonzalez-Perez V, Casanova Ramón-Borja JL, Martín García I, Barrios Benito M, Pelechano Gómez P, Rubio-Briones J, Rupérez MJ and Martín-Guerrero JD. Deep learning for fully automatic detection, segmentation, and Gleason grade estimation of prostate cancer in multiparametric magnetic resonance images. Sci Rep 2022; 12: 2975.

[15] Sanford T, Harmon SA, Turkbey EB, Kesani D, Tuncer S, Madariaga M, Yang C, Sackett J, Mehralivand S, Yan P, Xu S, Wood BJ, Merino MJ, Pinto PA, Choyke PL and Turkbey B. Deep-learning-based artificial intelligence for PI-RADS classification to assist multiparametric prostate MRI interpretation: a development study. J Magn Reson Imaging 2020; 52: 1499-1507.

[16] Gavade AB, et al. Automated diagnosis of prostate cancer using mpmri images: a deep learning approach for clinical decision support. Computers 2023; 12: 152.

[17] Xu Y, Wang R, Fang Z and Tang J. Feasibility study of AI-assisted multi-parameter MRI diagnosis of prostate cancer. Sci Rep 2025; 15: 10530.

[18] Yao F, Lin H, Xue YN, Zhuang YD, Bian SY, Zhang YY, Yang YJ and Pan KH. Multimodal imaging deep learning model for predicting extraprostatic extension in prostate cancer using MpMRI and 18 F-PSMA-PET/CT. Cancer Imaging 2025; 25: 103.

[19] Yu J, Xiao B, Wang J, Mi H, Wang E, Huang N, Zhou Y, Zhang D, Luo F, Yang L, Lin H, Huang R, Ding Y, Li X, Xu C, Lyu G and Chen M. Weakly supervised deep learning for multimodal MRI-TRUS registration: toward assisting prostate biopsy guidance. Digit Health 2025; 11: 20552076251375870.

[20] Taguelmimt K, Andrade-Miranda G, Harb H, Thanh TT, Dang HP, Malavaud B and Bert J. Towards more reliable prostate cancer detection: incorporating clinical data and uncertainty in MRI deep learning. Comput Biol Med 2025; 194: 110440.

[21] Khosravi P, Saikali S, Alipour A, Mohammadi S, Boger M, Diallo DM, Smith CJ, Moschovas MC, Hajirasouliha I, Hung AJ, Venkataraman SS and Patel V. AutoRadAI: a versatile artificial intelligence framework validated for detecting extracapsular extension in prostate cancer. Biol Methods Protoc 2025; 10: bpaf032.

[22] Moroianu ŞL, Bhattacharya I, Seetharaman A, Shao W, Kunder CA, Sharma A, Ghanouni P, Fan RE, Sonn GA and Rusu M. Computational detection of extraprostatic extension of prostate cancer on multiparametric MRI using deep learning. Cancers (Basel) 2022; 14: 2821.

[23] Simon BD, Merriman KM, Harmon SA, Tetreault J, Yilmaz EC, Blake Z, Merino MJ, An JY, Marko J, Law YM, Gurram S, Wood BJ, Choyke PL, Pinto PA and Turkbey B. Automated detection and grading of extraprostatic extension of prostate cancer at MRI via cascaded deep

learning and random forest classification. Acad Radiol 2024; 31: 4096-4106.
[24] Song Y, Dornisch AM, Dess RT, Margolis DJA, Weinberg EP, Barrett T, Cornell M, Fan RE, Harisinghani M, Kamran SC, Lee JH, Li CX, Liss MA, Rusu M, Santos J, Sonn GA, Vidic I, Woolen SA, Dale AM and Seibert TM. Multidisciplinary consensus prostate contours on magnetic resonance imaging: educational atlas and reference standard for artificial intelligence benchmarking. Int J Radiat Oncol Biol Phys 2025; 123: 183-194.
[25] Mendes B, Domingues I and Santos J. Radiomic pipelines for prostate cancer in external beam radiation therapy: a review of methods and future directions. J Clin Med 2024; 13: 3907.
[26] Riaz IB, Harmon S, Chen Z, Naqvi SAA and Cheng L. Applications of artificial intelligence in prostate cancer care: a path to enhanced efficiency and outcomes. Am Soc Clin Oncol Educ Book 2024; 44: e438516.
[27] Bulten W, Kartasalo K, Chen PC, Ström P, Pinckaers H, Nagpal K, Cai Y, Steiner DF, van Boven H, Vink R, Hulsbergen-van de Kaa C, van der Laak J, Amin MB, Evans AJ, van der Kwast T, Allan R, Humphrey PA, Grönberg H, Samaratunga H, Delahunt B, Tsuzuki T, Häkkinen T, Egevad L, Demkin M, Dane S, Tan F, Valkonen M, Corrado GS, Peng L, Mermel CH, Ruusuvuori P, Litjens G and Eklund M; PANDA challenge consortium. Artificial intelligence for diagnosis and Gleason grading of prostate cancer: the PANDA challenge. Nat Med 2022; 28: 154-163.
[28] Bulten W, Pinckaers H, van Boven H, Vink R, de Bel T, van Ginneken B, van der Laak J, Hulsbergen-van de Kaa C and Litjens G. Automated deep-learning system for Gleason grading of prostate cancer using biopsies: a diagnostic study. Lancet Oncol 2020; 21: 233-241.
[29] Qiu J, Chen Q, Lan W and Cao J. Multichannel contribution aware network for prostate cancer grading in histopathology images. J Comput Biol 2025; 32: 826-837.
[30] Nagpal K, Foote D, Tan F, Liu Y, Chen PC, Steiner DF, Manoj N, Olson N, Smith JL, Mohtashamian A, Peterson B, Amin MB, Evans AJ, Sweet JW, Cheung C, van der Kwast T, Sangoi AR, Zhou M, Allan R, Humphrey PA, Hipp JD, Gadepalli K, Corrado GS, Peng LH, Stumpe MC and Mermel CH. Development and validation of a deep learning algorithm for gleason grading of prostate cancer from biopsy specimens. JAMA Oncol 2020; 6: 1372-1380.
[31] Ankolekar A, Boie S, Abdollahyan M, Gadaleta E, Hasheminasab SA, Yang G, Beauville C, Dikaios N, Kastis GA, Bussmann M, Chelala C, Khalid S, Kruger H, Lambin P and Papanastasiou G; OPTIMA Consortium. Advancing breast, lung and prostate cancer research with federated learning. A systematic review. NPJ Digit Med 2025; 8: 314.
[32] Dai F, He Y, Duan J, Lin K, Lv Q, Zhao Z, Zou Y, Jiang J, Zheng Z and Qiu X. Global trends in the use of artificial intelligence for urological tumor histopathology: a 20-year bibliometric analysis. Digit Health 2025; 11: 20552076251348834.
[33] Schoenpflug LA, Nie Y, Sheikhzadeh F and Koelzer VH. A review on federated learning in computational pathology. Comput Struct Biotechnol J 2024; 23: 3938-3945.
[34] Madabhushi A and Lee G. Image analysis and machine learning in digital pathology: challenges and opportunities. Med Image Anal 2016; 33: 170-175.
[35] Sagiv C, Hadar O, Najjar A and Pahnke J. Artificial intelligence in surgical pathology - Where do we stand, where do we go? Eur J Surg Oncol 2025; 51: 109541.
[36] Lough L, Sheng M, Namekawa T, Ion-Margineanu A, Freudiger CW, Taneja SS and Mannas MP. Detection and isolation of cancer in prostate biopsies using stimulated raman histology and artificial intelligence. J Vis Exp 2025.
[37] Zhang DY, Sali R, Zhu M and Zhang V. Introduction of an integrated pathology image management, artificial intelligence, and reporting system. J Vis Exp 2025.
[38] Krishnan Nambudiri MK, Sujadevi VG, Poornachandran P, Murali Krishna C, Kanno T and Noothalapati H. Artificial intelligence-assisted stimulated raman histology: new frontiers in vibrational tissue imaging. Cancers (Basel) 2024; 16: 3917.
[39] Esteva A, Feng J, van der Wal D, Huang SC, Simko JP, DeVries S, Chen E, Schaeffer EM, Morgan TM, Sun Y, Ghorbani A, Naik N, Nathawani D, Socher R, Michalski JM, Roach M 3rd, Pisansky TM, Monson JM, Naz F, Wallace J, Ferguson MJ, Bahary JP, Zou J, Lungren M, Yeung S, Ross AE; NRG Prostate Cancer AI Consortium; Sandler HM, Tran PT, Spratt DE, Pugh S, Feng FY and Mohamad O. Prostate cancer therapy personalization via multi-modal deep learning on randomized phase III clinical trials. NPJ Digit Med 2022; 5: 71.
[40] Lin H, Yao F, Yi X, Yuan Y, Xu J, Chen L, Wang H, Zhuang Y, Lin Q, Xue Y, Yang Y and Pan Z. Prediction of adverse pathology in prostate cancer using a multimodal deep learning approach based on [(18)F]PSMA-1007 PET/CT and multiparametric MRI. Eur J Nucl Med Mol Imaging 2025; 52: 2814-2825.
[41] Singh S, Pathak AK, Kural S, Kumar L, Bhardwaj MG, Yadav M, Trivedi S, Das P, Gupta M and Jain G. Integrating miRNA profiling and

machine learning for improved prostate cancer diagnosis. Sci Rep 2025; 15: 30477.
[42] Italiano A, Gautier O, Dupont J, Assi T, Dawi L, Lawrance L, Bone A, Jardali G, Choucair A, Ammari S, Bayle A, Rouleau E, Cournede PH, Borget I, Besse B, Barlesi F, Massard C and Lassau N. The correlation of liquid biopsy genomic data to radiomics in colon, pancreatic, lung and prostatic cancer patients. Eur J Cancer 2025; 226: 115609.
[43] Roest C, Yakar D, Rener Sitar DI, Bosma JS, Rouw DB, Fransen SJ, Huisman H and Kwee TC. Multimodal AI combining clinical and imaging inputs improves prostate cancer detection. Invest Radiol 2024; 59: 854-860.
[44] Vakili S, Beheshti I, Barzegar Behrooz A, Łos MJ, Vitorino R and Ghavami S. Transforming prostate cancer care: innovations in diagnosis, treatment, and future directions. Int J Mol Sci 2025; 26: 5386.
[45] Vasconcelos Ordones F, Kawano PR, Vermeulen L, Hooshyari A, Scholtz D, Gilling PJ, Foreman D, Kaufmann B, Poyet C, Gorin M, Barbosa AMP, da Rocha NC and de Andrade LGM. A novel machine learning-based predictive model of clinically significant prostate cancer and online risk calculator. Urology 2025; 196: 20-26.
[46] Jadhav A, Gupte A, Rasal S, Awate O and Dandekar PR. Evaluation of the efficacy of automated machine learning enhanced planning system and a comparative analysis with manual planning system. J Cancer Res Ther 2025; 21: 593-601.
[47] Huo X, Kohli M and Finkelstein J. Using machine learning to predict survival in patients with metastatic castration-resistant prostate cancer. Stud Health Technol Inform 2025; 323: 169-173.
[48] Lee RS, Ma R, Pham S, Maya-Silva J, Nguyen JH, Aron M, Cen S, Daneshmand S and Hung AJ. Machine learning to delineate surgeon and clinical factors that anticipate positive surgical margins after robot-assisted radical prostatectomy. J Endourol 2022; 36: 1192-1198.
[49] Gan G, Xu Y, Wang Y, Mo Z, Jia L, Xu X, Gong W and Qin S. A study of criteria-based online adaptive radiotherapy with radiomics and dosimetry for postoperative prostate cancer. Med Phys 2025; 52: e18058.
[50] Hwang J, Kang BH, Park Y, Choi DH, Kim JS, Cho S and Lee E. Improving segmentation precision in prostate cancer adaptive radiation therapy with a patient-specific network. PLoS One 2025; 20: e0332603.
[51] Feng H, Shan J, Vargas CE, Keole SR, Rwigema JM, Yu NY, Ding Y, Zhang L, Hu Y, Schild SE, Wong WW, Vora SA, Shen J and Liu W. Online adaptive proton therapy facilitated by artificial intelligence-based autosegmentation in pencil beam scanning proton therapy. Int J Radiat Oncol Biol Phys 2025; 121: 822-831.
[52] Lau HM, Qu LG and Woon DTS. Advances in techniques in radical prostatectomy. Medicina (Kaunas) 2025; 61: 1222.
[53] Checcucci E, Piana A, Volpi G, Piazzolla P, Amparore D, De Cillis S, Piramide F, Gatti C, Stura I, Bollito E, Massa F, Di Dio M, Fiori C and Porpiglia F. Three-dimensional automatic artificial intelligence driven augmented-reality selective biopsy during nerve-sparing robot-assisted radical prostatectomy: a feasibility and accuracy study. Asian J Urol 2023; 10: 407-415.
[54] Bianchi L, Chessa F, Angiolini A, Cercenelli L, Lodi S, Bortolani B, Molinaroli E, Casablanca C, Droghetti M, Gaudiano C, Mottaran A, Porreca A, Golfieri R, Romagnoli D, Giunchi F, Fiorentino M, Piazza P, Puliatti S, Diciotti S, Marcelli E, Mottrie A and Schiavina R. The use of augmented reality to guide the intraoperative frozen section during robot-assisted radical prostatectomy. Eur Urol 2021; 80: 480-488.
[55] Boellaard TN, van Erck R, van der Graaf SH, de Boer L, van der Poel HG, Mertens LS, van Leeuwen PJ and Dashtbozorg B. Comparing AI and manual segmentation of prostate MRI: towards AI-driven 3D-model-guided prostatectomy. Diagnostics (Basel) 2025; 15: 1141.
[56] Mei H, Yang R, Huang J, Jiao P, Liu X, Chen Z, Chen H and Zheng Q. Artificial intelligence-assisted segmentation of prostate tumors and neurovascular bundles: applications in precision surgery for prostate cancer. Ann Surg Oncol 2025; [Epub ahead of print].
[57] Cianflone F, Maris B, Bertolo R, Veccia A, Artoni F, Pettenuzzo G, Montanaro F, Porcaro AB, Bianchi A, Malandra S, Ditonno F, Cerruto MA, Zamboni G, Fiorini P and Antonelli A. Development of artificial intelligence-based real-time automatic fusion of multiparametric magnetic resonance imaging and transrectal ultrasonography of the prostate. Urology 2025; 199: 27-34.
[58] Gon Park S, Park J, Rock Choi H, Ho Lee J, Tae Cho S, Goo Lee Y, Ahn H and Pak S. Deep learning model for real-time semantic segmentation during intraoperative robotic prostatectomy. Eur Urol Open Sci 2024; 62: 47-53.
[59] Hashemi N, Mose M, Østergaard LR, Bjerrum F, Hashemi M, Svendsen MBS, Friis ML, Tolsgaard MG and Rasmussen S. Video-based robotic surgical action recognition and skills assessment on porcine models using deep learning. Surg Endosc 2025; 39: 1709-1719.
[60] Beyaz S, Özgözen AL, Turgut N and Ölke HC. Artificial intelligence and robotic surgery in clinical medicine: progress, challenges, and

future directions. Future Sci OA 2025; 11: 2540742.
[61] Chen S, Liu R, Duan S, Zhang B, Wang Y, Li X, Zhao Y, Li Z, Zhou Q, Zhang R, Zhang L, Xu X, Jang R, Zhang J, Li Y, Cai X and Zhang L. Ultrasound-guided percutaneous radiofrequency ablation combined with anti-PD-1 for the treatment of prostate cancer: an experimental study. Front Oncol 2025; 15: 1527763.
[62] Fassia MK, Balasubramanian A, Woo S, Vargas HA, Hricak H, Konukoglu E and Becker AS. Deep learning prostate mri segmentation accuracy and robustness: a systematic review. Radiol Artif Intell 2024; 6: e230138.
[63] Moreira P, Tuncali K, Tempany C and Tokuda J. AI-based isotherm prediction for focal cryoablation of prostate cancer. Acad Radiol 2023; 30 Suppl 1: S14-S20.
[64] Le Nobin J, Rosenkrantz AB, Villers A, Orczyk C, Deng FM, Melamed J, Mikheev A, Rusinek H and Taneja SS. Image guided focal therapy for magnetic resonance imaging visible prostate cancer: defining a 3-dimensional treatment margin based on magnetic resonance imaging histology co-registration analysis. J Urol 2015; 194: 364-70.
[65] Beek E, Hata N, Tuncali K and Moreira P. Image-guided adaptive cryotherapy for prostate cancer treatment. Ann Biomed Eng 2025; [Epub ahead of print].
[66] Sato K, Sakamoto S, Saito S, Shibata H, Yamada Y, Takeuchi N, Goto Y, Tomokazu S, Imamura Y, Ichikawa T and Kawakami E. Time-dependent personalized prognostic analysis by machine learning in biochemical recurrence after radical prostatectomy: a retrospective cohort study. BMC Cancer 2024; 24: 1446.
[67] Pinckaers H, van Ipenburg J, Melamed J, De Marzo A, Platz EA, van Ginneken B, van der Laak J and Litjens G. Predicting biochemical recurrence of prostate cancer with artificial intelligence. Commun Med (Lond) 2022; 2: 64.
[68] Huang E, Tran J, Huynh LM, Skarecky D, Wilson RH and Ahlering T. Prostate-specific antigen doubling time kinetics following radical prostatectomy to guide need for treatment intervention: validation of low-risk recurrences. Cancers (Basel) 2022; 14: 4087.
[69] Janbain A, Farolfi A, Guenegou-Arnoux A, Romengas L, Scharl S, Fanti S, Serani F, Peeken JC, Katsahian S, Strouthos I, Ferentinos K, Koerber SA, Vogel ME, Combs SE, Vrachimis A, Morganti AG, Spohn SK, Grosu AL, Ceci F, Henkenberens C, Kroeze SG, Guckenberger M, Belka C, Bartenstein P, Hruby G, Emmett L, Omerieh AA, Schmidt-Hegemann NS, Mose L, Aebersold DM, Zamboglou C, Wiegel T and Shelan M. A machine learning approach for predicting biochemical outcome after PSMA-PET-guided salvage radiotherapy in recurrent prostate cancer after radical prostatectomy: retrospective study. JMIR Cancer 2024; 10: e60323.
[70] Liu J, Zhang H, Woon DTS, Perera M and Lawrentschuk N. Predicting biochemical recurrence of prostate cancer post-prostatectomy using artificial intelligence: a systematic review. Cancers (Basel) 2024; 16; 3596.
[71] Jiang H, Ji L, Zhu L, Wang H and Mao F. XGBoost model for predicting erectile dysfunction risk after radical prostatectomy: development and validation using machine learning. Discov Oncol 2025; 16: 810.
[72] Amparore D, De Cillis S, Alladio E, Sica M, Piramide F, Verri P, Checcucci E, Piana A, Quarà A, Cisero E, Manfredi M, Di Dio M, Fiori C and Porpiglia F. Development of machine learning algorithm to predict the risk of incontinence after robot-assisted radical prostatectomy. J Endourol 2024; 38: 871-878.
[73] Saikali S, Reddy S, Gokaraju M, Goldsztein N, Dyer A, Gamal A, Jaber A, Moschovas M, Rogers T, Vangala A, Briscoe J, Toleti C, Patel P and Patel V. Development and assessment of an AI-based machine learning model for predicting urinary continence and erectile function recovery after robotic-assisted radical prostatectomy: insights from a prostate cancer referral center. Comput Methods Programs Biomed 2025; 259: 108522.
[74] Roach M 3rd, Zhang J, Mohamad O, van der Wal D, Simko JP, DeVries S, Huang HC, Joun S, Schaeffer EM, Morgan TM, Keim-Malpass J, Chen E, Yamashita R, Monson JM, Naz F, Wallace J, Bahary JP, Wilke D, Batra S, Biedermann GB, Faria S, Hwang L, Sandler HM, Spratt DE, Pugh SL, Esteva A, Tran PT and Feng FY. Assessing algorithmic fairness with a multimodal artificial intelligence model in men of african and non-african origin on NRG oncology prostate cancer phase III trials. JCO Clin Cancer Inform 2025; 9: e2400284.
[75] Agarwal R, Bjarnadottir M, Rhue L, Dugas M, Crowley K, Clark J and Gao G. Addressing algorithmic bias and the perpetuation of health inequities: an AI bias aware framework. Health Policy Technol 2023; 12: 100702.
[76] Rajagopal A, Redekop E, Kemisetti A, Kulkarni R, Raman S, Sarma K, Magudia K, Arnold CW and Larson PEZ. Federated learning with research prototypes: application to multi-center MRI-based detection of prostate cancer with diverse histopathology. Acad Radiol 2023; 30: 644-657.
[77] Hamm CA, Baumgärtner GL, Biessmann F, Beetz NL, Hartenstein A, Savic LJ, Froböse K, Dräger F, Schallenberg S, Rudolph M, Baur ADJ, Hamm B, Haas M, Hofbauer S, Cash H

and Penzkofer T. Interactive explainable deep learning model informs prostate cancer diagnosis at MRI. Radiology 2023; 307: e222276.

[78] Gunashekar DD, Bielak L, Hägele L, Oerther B, Benndorf M, Grosu AL, Brox T, Zamboglou C and Bock M. Explainable AI for CNN-based prostate tumor segmentation in multi-parametric MRI correlated to whole mount histopathology. Radiat Oncol 2022; 17: 65.

[79] Westhaeusser F, Fuhlert P, Dietrich E, Lennartz M, Khatri R, Kaiser N, Röbeck P, Bülow R, von Stillfried S, Witte A, Ladjevardi S, Drotte A, Severgardh P, Baumbach J, Puelles VG, Häggman M, Brehler M, Boor P, Walhagen P, Dragomir A, Busch C, Graefen M, Bengtsson E, Sauter G, Zimmermann M and Bonn S. Robust, credible, and interpretable AI-based histopathological prostate cancer grading. medRxiv [Preprint] 2024.

[80] Rosenbacke R, Melhus Å, McKee M and Stuckler D. How explainable artificial intelligence can increase or decrease clinicians' trust in AI applications in health care: systematic review. JMIR AI 2024; 3: e53207.

[81] Intelligence A and Learning M. Based software as a medical device (samd) action plan. Food and Drug Administration 2021: 2021-06.

[82] Tejani AS, Cook TS, Hussain M, Sippel Schmidt T and O'Donnell KP. Integrating and adopting ai in the radiology workflow: a primer for standards and integrating the healthcare enterprise (IHE) profiles. Radiology 2024; 311: e232653.

[83] Naqvi SAA, Ayub U, Khan MA, Khoury PR, Ravichandar DB, Witte OH, Childs DS, Orme J, Zakharia Y, Singh P, Bryce AH and Riaz IB. Large language models (LLMs) for inferring genomic characteristics and facilitating genomic literacy in prostate cancer (PCa) patients. 2025, American Society of Clinical Oncology.

[84] Li M, Huang J, Yeung J, Blaes A, Johnson S, Liu H, Xu H and Zhang R. Cancerllm: a large language model in cancer domain. arXiv preprint arXiv:2406.10459, 2024.

[85] Guo Y, Li T, Gong B, Hu Y, Wang S, Yang L and Zheng C. From images to genes: radiogenomics based on artificial intelligence to achieve non-invasive precision medicine in cancer patients. Adv Sci (Weinh) 2025; 12: e2408069.

[86] Unger M and Kather JN. A systematic analysis of deep learning in genomics and histopathology for precision oncology. BMC Med Genomics 2024; 17: 48.

[87] Engesser C, Henkel M, Stalder AF, Tobias H, Trotsenko P, Alargkof V, Cornford P, Seifert H, Stieltjes B and Wetterauer C. Accompanying the prostate cancer patient pathway: evaluation of novel clinical decision support software in patients with early diagnosis of prostate cancer. BMC Med Inform Decis Mak 2025; 25: 260.